1. Home
  2. KPTI
  3. KPTI News

Latest Karyopharm Therapeutics Inc. (KPTI) News on April 15, 2025

KPTI

MT Newswires

12 days ago

RBC Lowers Price Target on Karyopharm Therapeutics to $43 From $45, Keeps Outperform Rating

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KPTI

PR Newswire

14 days ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Biotech stocks slide as Marks resignation seen being negative for sector
KPTI

TipRanks

14 days ago

Biotech stocks slide as Marks resignation seen being negative for sector

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KPTI

PR Newswire

a month ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KPTI

MT Newswires

2 months ago

Karyopharm Therapeutics to Implement 1-for-15 Reverse Stock Split

Karyopharm Announces 1-for-15 Reverse Stock Split
KPTI

PR Newswire

2 months ago

Karyopharm Announces 1-for-15 Reverse Stock Split

Karyopharm Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
KPTI

Simply Wall St.

2 months ago

Karyopharm Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Karyopharm Therapeutics Inc (KPTI) Q4 2024 Earnings Call Highlights: Navigating Revenue ...
KPTI

GuruFocus.com

2 months ago

Karyopharm Therapeutics Inc (KPTI) Q4 2024 Earnings Call Highlights: Navigating Revenue ...

KPTI

Thomson Reuters StreetEvents

2 months ago

Q4 2024 Karyopharm Therapeutics Inc Earnings Call

Karyopharm Therapeutics (KPTI) Q4 2024 Earnings Call Transcript
KPTI

Motley Fool

2 months ago

Karyopharm Therapeutics (KPTI) Q4 2024 Earnings Call Transcript

Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates
KPTI

Zacks

2 months ago

Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates

KPTI

Associated Press Finance

2 months ago

Karyopharm Therapeutics: Q4 Earnings Snapshot

Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress
KPTI

PR Newswire

2 months ago

Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

Karyopharm Therapeutics Inc (KPTI) Q4 2024 Earnings Report Preview: What To Look For
KPTI

GuruFocus.com

2 months ago

Karyopharm Therapeutics Inc (KPTI) Q4 2024 Earnings Report Preview: What To Look For

Analysts Estimate Indivior PLC (INDV) to Report a Decline in Earnings: What to Look Out for
KPTI

Zacks

2 months ago

Analysts Estimate Indivior PLC (INDV) to Report a Decline in Earnings: What to Look Out for

Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025
KPTI

PR Newswire

2 months ago

Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KPTI

PR Newswire

2 months ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verve Therapeutics (VERV) Moves 18.7% Higher: Will This Strength Last?
KPTI

Zacks

3 months ago

Verve Therapeutics (VERV) Moves 18.7% Higher: Will This Strength Last?

Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives
KPTI

PR Newswire

3 months ago

Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives

Why Karyopharm Therapeutics (KPTI) Is Among the Best Penny Stocks to Invest In According to Media?
KPTI

Insider Monkey

3 months ago

Why Karyopharm Therapeutics (KPTI) Is Among the Best Penny Stocks to Invest In According to Media?

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KPTI

PR Newswire

3 months ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KPTI

MT Newswires

3 months ago

Karyopharm Therapeutics Names Lori Macomber CFO

Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer
KPTI

PR Newswire

3 months ago

Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer

Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications
KPTI

PR Newswire

4 months ago

Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications

Karyopharm Therapeutics Provides Endometrial Cancer Program Update
KPTI

PR Newswire

4 months ago

Karyopharm Therapeutics Provides Endometrial Cancer Program Update

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KPTI

PR Newswire

4 months ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference
KPTI

PR Newswire

5 months ago

Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference

KPTI

MT Newswires

5 months ago

Karyopharm Therapeutics Appoints Kristin Abate as Chief Accounting Officer

Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer
KPTI

PR Newswire

5 months ago

Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer

Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition
KPTI

PR Newswire

5 months ago

Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
KPTI

Simply Wall St.

5 months ago

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Karyopharm Therapeutics Third Quarter 2024 Earnings: Beats Expectations
KPTI

Simply Wall St.

5 months ago

Karyopharm Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Karyopharm Therapeutics Inc (KPTI) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ...
KPTI

GuruFocus.com

5 months ago

Karyopharm Therapeutics Inc (KPTI) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ...

Karyopharm Therapeutics (KPTI) Q3 2024 Earnings Call Transcript
KPTI

Motley Fool

5 months ago

Karyopharm Therapeutics (KPTI) Q3 2024 Earnings Call Transcript

Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates
KPTI

Zacks

5 months ago

Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates

KPTI

Associated Press Finance

5 months ago

Karyopharm Therapeutics: Q3 Earnings Snapshot

Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress
KPTI

PR Newswire

5 months ago

Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Karyopharm Therapeutics Inc (KPTI) Q3 2024: Everything You Need To Know Ahead Of Earnings
KPTI

GuruFocus.com

5 months ago

Karyopharm Therapeutics Inc (KPTI) Q3 2024: Everything You Need To Know Ahead Of Earnings

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KPTI

PR Newswire

5 months ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Earnings Preview: Amneal Pharmaceuticals (AMRX) Q3 Earnings Expected to Decline
KPTI

Zacks

5 months ago

Earnings Preview: Amneal Pharmaceuticals (AMRX) Q3 Earnings Expected to Decline

Karyopharm Therapeutics (KPTI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
KPTI

Zacks

5 months ago

Karyopharm Therapeutics (KPTI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024
KPTI

PR Newswire

6 months ago

Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024

Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis
KPTI

PR Newswire

6 months ago

Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis

Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024
KPTI

PR Newswire

6 months ago

Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024

Highbridge Capital Management's Strategic Acquisition of Karyopharm Therapeutics Shares
KPTI

GuruFocus.com

6 months ago

Highbridge Capital Management's Strategic Acquisition of Karyopharm Therapeutics Shares

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KPTI

PR Newswire

6 months ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Down -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics (KPTI) Looks Ripe for a Turnaround
KPTI

Zacks

7 months ago

Down -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics (KPTI) Looks Ripe for a Turnaround

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KPTI

PR Newswire

7 months ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm to Participate at Upcoming Investor Conferences
KPTI

PR Newswire

7 months ago

Karyopharm to Participate at Upcoming Investor Conferences

Pipeline Moves: Investigator-led oncology cell therapy trial terminated
KPTI

Clinical Trials Arena

7 months ago

Pipeline Moves: Investigator-led oncology cell therapy trial terminated

With 58% ownership, Karyopharm Therapeutics Inc. (NASDAQ:KPTI) boasts of strong institutional backing
KPTI

Simply Wall St.

8 months ago

With 58% ownership, Karyopharm Therapeutics Inc. (NASDAQ:KPTI) boasts of strong institutional backing

KPTI

Thomson Reuters StreetEvents

8 months ago

Q2 2024 Karyopharm Therapeutics Inc Earnings Call

Karyopharm Therapeutics (KPTI) Q2 2024 Earnings Call Transcript
KPTI

Motley Fool

8 months ago

Karyopharm Therapeutics (KPTI) Q2 2024 Earnings Call Transcript

Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates
KPTI

Zacks

8 months ago

Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates

KPTI

Associated Press Finance

8 months ago

Karyopharm Therapeutics: Q2 Earnings Snapshot

Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
KPTI

PR Newswire

8 months ago

Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KPTI

PR Newswire

8 months ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024
KPTI

PR Newswire

8 months ago

Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024

Earnings Preview: Assertio (ASRT) Q2 Earnings Expected to Decline
KPTI

Zacks

8 months ago

Earnings Preview: Assertio (ASRT) Q2 Earnings Expected to Decline

Karyopharm Therapeutics Inc. (KPTI): Is This One-Dollar Stock a Strong Buy Right Now?
KPTI

Insider Monkey

9 months ago

Karyopharm Therapeutics Inc. (KPTI): Is This One-Dollar Stock a Strong Buy Right Now?

Karyopharm Therapeutics Inc. (KPTI): Is This Penny Stock A Good Buy Right Now?
KPTI

Insider Monkey

9 months ago

Karyopharm Therapeutics Inc. (KPTI): Is This Penny Stock A Good Buy Right Now?

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KPTI

PR Newswire

9 months ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KPTI

MT Newswires

10 months ago

HC Wainwright Adjusts Price Target on Karyopharm Therapeutics to $7 From $8, Maintains Buy Rating

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KPTI

PR Newswire

10 months ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
KPTI

PR Newswire

10 months ago

Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates

Karyopharm to Participate at the Jefferies Global Healthcare Conference
KPTI

PR Newswire

a year ago

Karyopharm to Participate at the Jefferies Global Healthcare Conference

Karyopharm Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
KPTI

Simply Wall St.

a year ago

Karyopharm Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2024 Earnings Call Transcript
KPTI

Insider Monkey

a year ago

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2024 Earnings Call Transcript

KPTI

GuruFocus.com

a year ago

Karyopharm Therapeutics Inc (KPTI) Q1 2024 Earnings Call Transcript Highlights: Navigating ...

KPTI

Thomson Reuters StreetEvents

a year ago

Q1 2024 Karyopharm Therapeutics Inc Earnings Call

Karyopharm Therapeutics (KPTI) Q1 2024 Earnings Call Transcript
KPTI

Motley Fool

a year ago

Karyopharm Therapeutics (KPTI) Q1 2024 Earnings Call Transcript

Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference
KPTI

PR Newswire

a year ago

Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference

KPTI

GuruFocus.com

a year ago

Karyopharm Therapeutics Reports Q1 2024 Financial Results: A Detailed Review

KPTI

Associated Press Finance

a year ago

Karyopharm Therapeutics: Q1 Earnings Snapshot

Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029
KPTI

PR Newswire

a year ago

Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029

Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
KPTI

PR Newswire

a year ago

Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024
KPTI

PR Newswire

a year ago

Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KPTI

PR Newswire

a year ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting
KPTI

PR Newswire

a year ago

Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KPTI

PR Newswire

a year ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences
KPTI

PR Newswire

a year ago

Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences

Insider Sell: President and CEO Richard Paulson Sells 99,844 Shares of Karyopharm Therapeutics ...
KPTI

GuruFocus.com

a year ago

Insider Sell: President and CEO Richard Paulson Sells 99,844 Shares of Karyopharm Therapeutics ...

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KPTI

PR Newswire

a year ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2023 Earnings Call Transcript
KPTI

Insider Monkey

a year ago

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2023 Earnings Call Transcript

KPTI

Thomson Reuters StreetEvents

a year ago

Q4 2023 Karyopharm Therapeutics Inc Earnings Call

Karyopharm Therapeutics (KPTI) Q4 2023 Earnings Call Transcript
KPTI

Motley Fool

a year ago

Karyopharm Therapeutics (KPTI) Q4 2023 Earnings Call Transcript

Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates
KPTI

Zacks

a year ago

Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates

KPTI

Associated Press Finance

a year ago

Karyopharm Therapeutics: Q4 Earnings Snapshot

Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
KPTI

PR Newswire

a year ago

Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
KPTI

InvestorPlace

a year ago

7 Biotech Penny Stocks on the Verge of Clinical Trial Victory

Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
KPTI

PR Newswire

a year ago

Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

Xencor (XNCR) Surges 13.4%: Is This an Indication of Further Gains?
KPTI

Zacks

a year ago

Xencor (XNCR) Surges 13.4%: Is This an Indication of Further Gains?

Ardelyx (ARDX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
KPTI

Zacks

a year ago

Ardelyx (ARDX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Will Karyopharm Therapeutics (KPTI) Report Negative Q4 Earnings? What You Should Know
KPTI

Zacks

a year ago

Will Karyopharm Therapeutics (KPTI) Report Negative Q4 Earnings? What You Should Know

Karyopharm Therapeutics (NASDAQ:KPTI) adds US$104m to market cap in the past 7 days, though investors from three years ago are still down 90%
KPTI

Simply Wall St.

a year ago

Karyopharm Therapeutics (NASDAQ:KPTI) adds US$104m to market cap in the past 7 days, though investors from three years ago are still down 90%

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KPTI

PR Newswire

a year ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

A Closer Look At Planet Image International Limited's (NASDAQ:YIBO) Impressive ROE
KPTI

Simply Wall St.

a year ago

A Closer Look At Planet Image International Limited's (NASDAQ:YIBO) Impressive ROE

Byline Bancorp Inc (BY) Reports Solid Growth in 2023 Earnings
KPTI

GuruFocus.com

a year ago

Byline Bancorp Inc (BY) Reports Solid Growth in 2023 Earnings

Why Eagle Bancorp Montana, Inc. (EBMT) is a Top Dividend Stock for Your Portfolio
KPTI

Zacks

a year ago

Why Eagle Bancorp Montana, Inc. (EBMT) is a Top Dividend Stock for Your Portfolio

Zentek Completes Study Quantifying Energy and Emission Savings of ZenGUARD(TM)-Enhanced HVAC Filters
KPTI

ACCESSWIRE

a year ago

Zentek Completes Study Quantifying Energy and Emission Savings of ZenGUARD(TM)-Enhanced HVAC Filters

Share on Social Networks: